Colon cancer detection by measuring DNA of cells collected from rectum: A pilot study
Completed
- Conditions
- Colorectal cancerinflammatory bowel diseaseCancerColorectal
- Registration Number
- ISRCTN30255103
- Lead Sponsor
- Colonix Medical Ltd (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 190
Inclusion Criteria
Two different groups of participants were recruited:
1. Consecutive outpatients presenting colorectal symptoms and selected for diagnostic full colonoscopy
2. Consecutive patients with clinical diagnosis of colorectal malignancies prepared for operations in the Royal Surrey County Hospital (Guildford)
Note: In this small pilot study there was no sex and age limitations. All patients were over 35 of age.
Exclusion Criteria
Extensive surgical interventions in the colorectal region in the past
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie DNA analysis of rectal exfoliated cells for colorectal cancer detection in ISRCTN30255103?
How does rectal mucosa DNA screening compare to standard-of-care colonoscopy in detecting early-stage colorectal cancer?
Which specific DNA biomarkers are evaluated in ISRCTN30255103 for predicting colorectal cancer risk and progression?
What are the potential false positive/negative rates and management strategies for rectal DNA screening in ISRCTN30255103?
Are there alternative non-invasive colorectal cancer screening methods like stool DNA tests or liquid biopsies that compare to rectal mucosa DNA analysis in ISRCTN30255103?